First in new class of drugs to significantly improve clearance of chronic hepatitis C virus from the body

VICTRELIS™ Approved in Canada: First in new class of drugs

By Guest Column —— Bio and Archives--August 3, 2011

Lifestyles | Comments | Back To Full Article

MONTREAL, - Merck announced today that VICTRELIS™ (boceprevir) has been approved in Canada for the treatment of chronic hepatitis C (CHC) genotype 1 infection in combination with the current standard therapy, peginterferon alpha and ribavirin (peg/riba), in adult patients (18 years and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous therapy.1

Read Full Article...

Welcome to CFP’s Comment Section!

The Comment section of online publications is the new front in the ongoing Cancel Culture Battle.

Big Tech and Big Media are gunning for the Conservative Voice—through their Comment Sections.

Canada Free Press wishes to stay in the fight, and we want our fans, followers, commenters there with us.

We ask only that commenters keep it civil, keep it clean.

Thank You for your patience and for staying aboard the CFP ‘Mother Ship’.

READ OUR Commenting Policy

CFP Comments

Comments

Support Canada Free Press

Recommended by Canada Free Press